MedMira Reaches Funding Agreement to Enable US Market Expansion

19-Aug-2008 - Canada

MedMira Inc. announced that it has entered in to an agreement in principal with an investor for the issuance of a CDN $650,000 convertible debenture. Under the terms of the agreement, the debenture will bear interest of 9% per annum and will mature four years from the date of close. The debenture is convertible in whole or in part into common shares of MedMira at $0.15 per share during the first two years. The conversion price will increase by 10% in year three and increase by an additional 10% in year four. This agreement is subject to approval of the TSX.

This investment will enable MedMira to fuel various growth-centered activities in US market, including expansion of the Company's product offering. MedMira will be pursuing regulatory approvals for new rapid tests for sexually transmitted diseases as well as advancements in the Reveal rapid HIV test currently being sold in this market.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests - SE Asia Latest Target Market in Growing Global Distributor Network

SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda - Three-Year Collaboration to look for Novel Cancer Treatments

Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board

ALTANA AG: Sale of pharmaceuticals business to Nycomed - Purchase price of approx. EUR4.5 billion

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform - Examination of product candidates for the prevention of HPV-associated diseases

Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

Market Opportunities Abound for Life Science Suppliers in Multi-Billion Dollar U.S. Market for Biodefense Research

MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors